Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT03172754 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT03172754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
Fox Chase Cancer Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 12, 2017
Completion date
April 6, 2027
Enrollment
98 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

renal cell carcinoma